NCT06652438Toboroz3. fázis
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
Randomized Study to Assess Revumenib in Combination With Azacitidine + Venetoclax in Adult Patients With Newly Diagnosed NPM1-mutated or KMT2A-rearranged AML Ineligible for Intensive Chemotherapy
Forrás: ClinicalTrials.gov · Utoljára frissítve: 2026. szept. 2.
Rövid összefoglaló (regiszter, angolul)
Treatment of patients with newly diagnosed AML who are not eligible for intensive chemotherapy has remained an area of high unmet medical need. The combination therapy with two medicines, azacitidine and venetoclax, is the usual plan of action. This has brought significant progress in the treatment, but it nevertheless is not curative and the disease does relapse over time. Revumenib blocks a specific molecule called menin in the cell nucleus. Some types of AML are reliant on menin working properly. These are leukemia cells with a change in the DNA, i.e. a mutation in the NPM1 or KMT2A gene. Revumenib can prevent the production of these types of leukemia cells by disrupting the production of this menin. The current study investigates whether adding revumenib to the combination therapy improves the prognosis for AML patients with a mutation in the NPM1 or KMT2A gene. This is a randomized, double-blind, placebo-controlled clinical study where subjects will be treated until disease progression, or development of side effects or death. From the moment of inclusion of the last patient, there will be a 4-year observational follow-up study in order to register survival duration and follow-up visits. Approximately 448 previously untreated patients with a mutation in the NPM1 or KMT2A gene and with newly diagnosed AML, who are not eligible for intensive chemotherapy. Patients must be ≥18 years of age.
- Állapot (regiszter)
- Toboroz
- Fázis (regiszter)
- 3. fázis
- Vizsgálattípus
- Beavatkozással járó
- Résztvevők száma
- 448 (tervezett)
- Első benyújtás
- 2024. okt. 2.
- Kezdés
- 2025. máj. 5.
- Elsődleges befejezés
- 2029. dec. 13.
- Fő szponzor
- Stichting Hemato-Oncologie voor Volwassenen Nederland
- Betegségek
- Akut mieloid leukémia (AML)
- NCT-szám
- NCT06652438
- EU CT-szám
- 2024-512733-32-00
Mit vállalsz
- Vizsgálat típusa: Beavatkozással járó · 3. fázis
- Tervezett résztvevők: 448
- 2025. máj. 5. és az elsődleges befejezés (2029. dec. 13.) között
- 197 helyszín, 18 országban
- Vizitek és vizsgálatok: kérdezd a vizsgálat csapatát, a regiszter nem sorolja fel őket
A(z) ClinicalTrials.gov regisztermezőiből összeállítva. A vizsgálat felépítését írja le.
Ki nem vehet részt
Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.
Kiket keres a vizsgálat
- Central confirmation of NPM1 mutation or KMT2A rearrangement in one of the dedicated central genetic laboratories.
- Age ≥ 18 years, no upper age limit.
- Patient is ineligible for intensive induction chemotherapy by meeting at least 1 of the following criteria: * ≥ 75 years of age: ineligible for intensive chemotherapy per physician's discretion (with an ECOG performance status 0-2). * 18-74 years: patient is not eligible for standard chemotherapy because any of the following co-morbidities: * ECOG performance status 2 or 3. * Cardiac history of chronic heart failure requiring treatment; or with an ejection fraction ≤50%; or chronic stable angina. * DLCO ≤ 65% or FEV1 ≤ 65%. * Creatinine clearance ≥ 30 mL/min to <45 ml/min calculated by the Cockcroft Gault formula. * Moderate hepatic impairment with total bilirubin > 1.5 to < 3.0 x upper limit of normal (ULN). * Any other comorbidity that the local physician assesses to be incompatible with intensive chemotherapy must be reviewed and approved by the Sponsor's (co-) Principal Investigator (written approval must be sent to before study enrolment).
- Patient must have a projected life expectancy of at least 12 weeks (as assessed by the treating physician).
- Patient must have a white cell blood (WBC) count of < 25 x 109/L. Hydroxyurea can be used prior to study enrolment to reduce the WBC count to meet this criterion.
- Adequate renal function as evidenced by serum creatinine ≤ 2.0 × upper limit of norm (ULN) or creatinine clearance >30 mL/min based on the Cockcroft-Gault glomerular filtration rate (GFR).
- Adequate hepatic function as evidenced by: * Serum total bilirubin ≤ 3.0 × ULN unless considered due to Gilbert's disease, or leukemic involvement following written approval by the sponsor (Co-)Principal Investigator (copy in ). * Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) ≤ 3.0 × ULN, unless considered due to leukemic involvement following written approval by the sponsor (Co-)Principal Investigator (copy in ).
- Female patient must: * be of nonchildbearing potential: o postmenopausal (defined as at least 1 year without any menses). o documented surgically sterile (e.g. documented hysterectomy, bilateral oophorectomy, bilateral salpingectomy or congenital sterile) or status post hysterectomy (at least 1 month prior to screening). * or, if of childbearing potential (not surgically sterile and not postmenopausal) agree to avoid pregnancy during the study and for 6 months after the final study drug administration. * and have a negative urine or serum pregnancy test at screening. * and, if heterosexually active, agree to consistently apply one highly effective* method of birth control in combination to a barrier method for the duration of the study and for 6 months after the final study drug administration. *Highly effective forms of birth control include - Consistent and correct usage of established hormonal contraceptives that inhibit ovulation for at least 1 month prior to taking study drug. (hormonal contraception is only a highly effective method of birth control, if a combined [estrogen and progestogen containing] hormonal contraception or a progestogen-only hormonal contraception - both associated with inhibition of ovulation - is used. - Established intrauterine device (IUD) or intrauterine system (IUS) - Bilateral tubal occlusion - Vasectomy - a vasectomy is highly effective contraception method provided the absence of sperm has been confirmed. If not, an additional highly effective method of contraception should be used. - Male is sterile due to a bilateral orchiectomy. * Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual activity during the entire period of risk associated with the study drug. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical study and the preferred and usual lifestyle of the patient. List is not all inclusive. Prior to enrolment, the investigator is responsible for confirming patient will utilize highly effective forms of birth control in combination with a barrier method according to locally accepted standards during the protocol defined period. * agree not to breastfeed starting at screening and throughout the study period. * agree not to donate ova starting at screening and throughout the study period, and for 6 months after the final study drug administration.
- Men must use a latex condom during any sexual contact with women of childbearing potential (WOCBP), even if they have undergone a successful vasectomy and must agree to avoid to father a child (while on therapy and for 6 months after the final study drug administration). In addition, their female partners of childbearing potential must use a highly effective method of birth control.
- Male patient must not donate sperm starting at screening and throughout the study period and for 6 months after the final study drug administration.
- Able to understand and willing to sign an informed consent form (ICF).
- Institutional Review Board/Independent Ethics Committee-approved written informed consent as per national regulations must be obtained from the patient prior to any study-related procedures (including consent for withdrawal of prohibited medication, if applicable). Exclusion Criteria: Subject has previously been treated for AML; a treatment period with hydroxyurea to control WBC counts is allowed; prior treatment with a hypomethylating agent for MDS-EB is not allowed; prior treatment with erythropoiesis-stimulating agents or luspatercept for MDS is allowed. 2. Acute promyelocytic leukemia (APL) with t(15;17)(q24.1;q21.2); PML-RARA; or one of the other pathognomonic variant chromosomal translocations / fusion genes. 3. AML with BCR-ABL1; or myeloid blast crisis of CML. 4. Significant active cardiac disease within 3 months prior to the start of study treatment, including: * New York Heart Association (NYHA) class III or IV congestive heart failure
- Myocardial infarction
- Unstable angina
- Severe cardiac arrhythmias
- Congenital long QT syndrome of family member with this condition QTcF >450 msec on screening electrogram for males and >470msec on screening electrogram for females (mean of triplicate recordings; calculated using Fridericia's correction). 5. Severe obstructive or restrictive ventilation disorder. 6. History of stroke or intracranial hemorrhage within 6 months prior to randomization. 7. Clinical symptoms suggestive of active central nervous system (CNS) leukemia or known CNS leukemia. Evaluation of cerebrospinal fluid (CSF) during screening is only required if there is a clinical suspicion of CNS involvement by leukemia during screening. 8. Active infection, including hepatitis B or hepatitis C or Human Immunodeficiency Virus (HIV) infection, that is uncontrolled prior to first dose of study treatment and may interfere with the study objectives or which could expose the patient to undue risk through the participation in the clinical trial; an infection controlled with an approved antibiotic/ antiviral/ antifungal treatment that is not a strong or moderate CYP3A inducer is allowed. Patients with COVID-19 infection can be enrolled, if the patient has no symptoms and was tested negative twice by PCR test prior to inclusion in the trial. 9. Immediate life-threatening, severe complications of leukemia such as uncontrolled bleeding and/or disseminated intravascular coagulation. 10. Conditions that limit the ingestion or gastrointestinal absorption of orally administered drugs. 11. Patient with a currently active second malignancy. Patients are not considered to have a currently active malignancy, if they have completed therapy and are considered by their physician to be at < 30% risk of relapse within one year. However, patients with the following history/concurrent conditions are allowed:
- Basal or squamous cell carcinoma of the skin;
- Carcinoma in situ of the cervix;
- Carcinoma in situ of the breast;
- Incidental histologic finding of prostate cancer. 12. Receipt of live, attenuated vaccine within 30 days prior to the study inclusion (NOTE: patient, if enrolled, should not receive live vaccine during the study and until 6 months after the therapy). 13. Severe neurological or psychiatric disorder interfering with ability to give an informed consent. 14. Contraindication to AZA or VEN (as per Summary of Product Characteristics (SmPC)). 15. Patient weighing <40 kg at registration. 16. Participation in other prospective studies with anti-leukemic and/or investigational agents. 17. Patient taking Dabigatran unless they can be transferred to other medications within ≥5 half-lives prior to dosing. Patients taking other P-gP transporter-sensitive medications (see Appendix H) should be properly monitored during the study if they cannot be transferred to other medications. 18. Patient taking known strong cytochrome P450 (CYP) 3A4 inducers (see Appendix G), unless they can be transferred to other medications within ≥5 half-lives prior to dosing. 19. The patient is a pregnant or lactating woman, or plans to become pregnant during the study. 20. Patient who has once been screened and randomized into this HO177 trial but was considered ineligible cannot re-enter this trial at a later date.
Életkor a regiszterben: 18 év – - · Nem: nők és férfiak · Egészséges önkénteseket nem fogad
Helyszínek (197)
Helyszínek a regiszter sorrendjében. Ha a profilodba mented a városodat, távolság szerint rendeződnek.
| Helyszín | Város | Ország | Helyszín állapota |
|---|---|---|---|
| Vorarlberger Krankenhaus-Betriebsgesellschaft mbH | Feldkirch | Ausztria | Toboroz |
| Kepler Universitaetsklinikum GmbH | Linz | Ausztria | Toboroz |
| SCRI CCCIT Ges.m.b.H. | Salzburg | Ausztria | Toboroz |
| Hanusch Krankenhaus der Wiener Gebietskrankenkasse | Vienna | Ausztria | Toboroz |
| AU-Adelaide-RAH | Adelaide | Ausztrália | Toborzás még nem indult |
| AU-Birtinya-SUNSHINECOASTUH General Information | Birtinya | Ausztrália | Toborzás még nem indult |
| AU-Brisbane-RBWH | Brisbane | Ausztrália | Toboroz |
| AU-Douglas-TOWNSVILLE | Douglas | Ausztrália | Toborzás még nem indult |
| AU-Melbourne-ALFRED | Melbourne | Ausztrália | Toboroz |
| AU-Melbourne-MONASH | Melbourne | Ausztrália | Toborzás még nem indult |
| AU-Perth-FSH | Perth | Ausztrália | Visszavonva |
| AU-Perth-SCGH | Perth | Ausztrália | Toborzás még nem indult |
| AU-Sydney-RNSH | Sydney | Ausztrália | Toborzás még nem indult |
| AU-Sydney-SVSH | Sydney | Ausztrália | Toborzás még nem indult |
| Institut Jules Bordet | Anderlecht | Belgium | Toboroz |
| Ziekenhuis Aan De Stroom | Antwerp | Belgium | Toboroz |
| Az St-Jan Brugge-Oostende A.V. | Brugge | Belgium | Toboroz |
| Universitair Ziekenhuis Gent | Gent | Belgium | Toboroz |
| UZ Brussel | Jette | Belgium | Toboroz |
| UZ Leuven | Leuven | Belgium | Toboroz |
| Centre Hospitalier Universitaire de Liège | Liège | Belgium | Toboroz |
| Cliniques Universitaires Saint-Luc | Sint-Lambrechts-Woluwe | Belgium | Toboroz |
| Centre Hospitalier Universitaire Dinant Godinne Sainte-Elisabeth-UCL-Namur | Yvoir | Belgium | Toboroz |
| CH-Aarau-KSA | Aarau | Svájc | Toboroz |
| CH-Basel-USB | Basel | Svájc | Toboroz |
| CH-Bellinzona-IOSI | Bellinzona | Svájc | Toboroz |
| CH-Bern-INSEL | Bern | Svájc | Toboroz |
| CH-Geneve (14)-HCUGE | Geneva | Svájc | Toboroz |
| CH-Zürich-USZ | Zurich | Svájc | Toborzás még nem indult |
| Charite Universitaetsmedizin Berlin KöR | Berlin | Németország | Toboroz |
| Vivantes Netzwerk fuer Gesundheit GmbH | Berlin | Németország | Toboroz |
| Universitaetsklinikum Knappschaftskrankenhaus Bochum GmbH | Bochum | Németország | Toboroz |
| Universitaetsklinikum Bonn AöR | Bonn | Németország | Toboroz |
| Gesundheit Nord gGmbH Klinikverbund Bremen | Bremen | Németország | Toboroz |
| Staedtisches Klinikum Braunschweig gGmbH | Brunswick | Németország | Toboroz |
| Klinikum Darmstadt GmbH | Darmstadt | Németország | Toboroz |
| KLINIKEN ESSEN SUED Evangelisches Krankenhaus Essen-Werden gGmbH | Essen | Németország | Toboroz |
| Malteser Norddeutschland gGmbH | Flensburg | Németország | Toboroz |
| Medical Center- University of Freiburg | Freiburg im Breisgau | Németország | Toboroz |
| Universitaetsmedizin Greifswald KöR | Greifswald | Németország | Toboroz |
| Martin-Luther-Universitaet Halle-Wittenberg | Halle (Saale) | Németország | Toboroz |
| Asklepios Klinik St George | Hamburg | Németország | Toboroz |
| University Medical Center Hamburg-Eppendorf | Hamburg | Németország | Toboroz |
| Klinikum Region Hannover GmbH | Hanover | Németország | Toboroz |
| Medizinische Hochschule Hannover | Hanover | Németország | Toboroz |
| SLK-Kliniken Heilbronn GmbH | Heilbronn | Németország | Toboroz |
| St. Elisabeth Gruppe GmbH Katholische Kliniken Rhein-Ruhr | Herne | Németország | Toboroz |
| Universitaet Des Saarlandes | Homburg | Németország | Toboroz |
| Staedtisches Klinikum Karlsruhe gGmbH | Karlsruhe | Németország | Toboroz |
| Otto Von Guericke Universitaet Magdeburg | Magdeburg | Németország | Toboroz |
| Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR | Mainz | Németország | Toboroz |
| Muehlenkreiskliniken AöR | Minden | Németország | Toboroz |
| Klinikum der Technischen Universitaet Muenchen (TUM Klinikum) | Munich | Németország | Toboroz |
| Klinikum Oldenburg Aor | Oldenburg | Németország | Toboroz |
| Klinikum Ernst von Bergmann gGmbH | Potsdam | Németország | Toboroz |
| Universitaetsklinikum Regensburg AöR | Regensburg | Németország | Toboroz |
| Klinikum Der Landeshauptstadt Stuttgart gKAöR | Stuttgart | Németország | Toboroz |
| Universitaetsklinikum Tuebingen AöR | Tuebingen | Németország | Toboroz |
| Universitaetsklinikum Ulm AoR | Ulm | Németország | Toboroz |
| Helios Universitaetsklinikum Wuppertal | Wuppertal | Németország | Toboroz |
| Aalborg University Hospital | Aalborg | Dánia | Toboroz |
| Region Midtjylland | Aarhus N | Dánia | Toboroz |
| Rigshospitalet | Copenhagen Oe | Dánia | Toboroz |
| Odense University Hospital | Odense C | Dánia | Toboroz |
| North Estonia Medical Centre Foundation | Tallinn | Észtország | Toboroz |
| Tartu University Hospital | Tartu Linn | Észtország | Toboroz |
| Institut Catala d'Oncologia | Badalona | Spanyolország | Toboroz |
| Hospital Clinic de Barcelona | Barcelona | Spanyolország | Toboroz |
| Hospital de la Santa Creu i Sant Pau | Barcelona | Spanyolország | Toboroz |
| Hospital del Mar | Barcelona | Spanyolország | Toboroz |
| Institut Català d'Oncologia | Girona | Spanyolország | Toboroz |
| Institut Catala D'oncologia | L'Hospitalet de Llobregat | Spanyolország | Toboroz |
| Hospital Universitari Arnau De Vilanova De La Gerencia Territorial De Lleida | Lleida | Spanyolország | Toboroz |
| Hospital General Universitario Gregorio Marañón | Madrid | Spanyolország | Toboroz |
| University Hospital Son Espases | Palma | Spanyolország | Toboroz |
| Hospital Universitari Joan XXIII de Tarragona | Tarragona | Spanyolország | Toboroz |
| Fundacio Assistencial De Mutua De Terrassa Fpc | Terrassa | Spanyolország | Toboroz |
| Hospital Clinico Universitario de Valencia | Valencia | Spanyolország | Toboroz |
| HUS-Yhtymae | Helsinki | Finnország | Toboroz |
| Pohjois-Pohjanmaan hyvinvointialue | Oulu | Finnország | Toboroz |
| Tampere University Hospital | Tampere | Finnország | Toboroz |
| Varsinais-Suomen hyvinvointialue | Turku | Finnország | Toboroz |
| Centre Hospitalier Universitaire Amiens Picardie | Amiens Cedex 1 | Franciaország | Toboroz |
| Centre Hospitalier Universitaire D'Angers | Angers | Franciaország | Toboroz |
| CHU Besancon | Besancon Cedex | Franciaország | Toboroz |
| Centre Hospitalier Universitaire De Caen Normandie | Caen Cedex 9 | Franciaország | Toboroz |
| Hopital D Instruction Des Armées Percy | Clamart | Franciaország | Toboroz |
| University Hospital Of Clermont-Ferrand | Clermont-Ferrand | Franciaország | Toboroz |
| Assistance Publique Hopitaux De Paris | Creteil Cedex | Franciaország | Toboroz |
| Centre Hospitalier Universitaire Grenoble Alpes | Grenoble Cedex 9 | Franciaország | Toboroz |
| Centre Hospitalier De Versailles | Le Chesnay Rocquencourt | Franciaország | Toboroz |
| Centre Hospitalier Universitaire De Lille | Lille Cedex | Franciaország | Toboroz |
| Centre Hospitalier Et Universitaire De Limoges | Limoges Cedex 1 | Franciaország | Toboroz |
| Centre Hospital Region Metz Thionville | Metz Cedex 03 | Franciaország | Toboroz |
| Centre Hospitalier Universitaire De Montpellier | Montpellier Cedex 5 | Franciaország | Toboroz |
| Centre Hospitalier Universitaire de Nantes | Nantes | Franciaország | Toboroz |
| Centre Hospitalier Universitaire de Nice | Nice | Franciaország | Toboroz |
| Centre Hospitalier Universitaire de Bordeaux | Pessac | Franciaország | Toboroz |
| Hospices Civils de Lyon | Pierre-Bénite | Franciaország | Toboroz |
| Centre Henri Becquerel | Rouen Cedex | Franciaország | Toboroz |
| Centre Hospitalier Universitaire de Saint Etienne | Saint-Priest-en-Jarez | Franciaország | Toboroz |
| Les Hopitaux Universitaires De Strasbourg | Strasbourg Cedex 2 | Franciaország | Toboroz |
| Belfasttrust | Belfast | Egyesült Királyság | Toborzás még nem indult |
| Birmingham-QE | Birmingham | Egyesült Királyság | Toborzás még nem indult |
| Blackpool Victoria | Blackpool | Egyesült Királyság | Toboroz |
| UK-Bodelwyddan-BCUHB | Bodelwyddan | Egyesült Királyság | Toborzás még nem indult |
| UK-Bristol-BRISTOLCENTRE | Bristol | Egyesült Királyság | Toboroz |
| University Hospital of Wales | Cardiff | Egyesült Királyság | Toboroz |
| UK-Portsmouth-QUEENALEXANDRA | Cosham | Egyesült Királyság | Toboroz |
| UK-Coventry-UHCOVENTRYANDWARWICKSHIRE | Coventry | Egyesült Királyság | Toboroz |
| UK-Derby-ROYALDERBYHOSPITAL | Derby | Egyesült Királyság | Toborzás még nem indult |
| UK-Edinburgh-WGH | Edinburgh | Egyesült Királyság | Toborzás még nem indult |
| Beatson West of Scotland Cancer Centre | Glasgow | Egyesült Királyság | Toboroz |
| UK-Harrow-NORTHWICK | Harrow | Egyesült Királyság | Toborzás még nem indult |
| UK-Hull-CASTLEHILL | Hull | Egyesült Királyság | Toboroz |
| St. James UH | Leeds | Egyesült Királyság | Toboroz |
| University Hospitals of Leicester NHS Trust | Leicester | Egyesült Királyság | Toboroz |
| King's College Hospital | London | Egyesült Királyság | Toboroz |
| University College Hospital | London | Egyesült Királyság | Toboroz |
| St. Bartholomew's Hospital | London | Egyesült Királyság | Toboroz |
| Christie NHS Foundation Trust | Manchester | Egyesült Királyság | Toboroz |
| UK-Manchester-ROYALINFIRMARY | Manchester | Egyesült Királyság | Toboroz |
| The Newcastle Upon Tyne Hospitals NHS Foundation Trust | Newcastle | Egyesült Királyság | Toboroz |
| Nottingham University Hospitals NHS Trust | Nottingham | Egyesült Királyság | Toboroz |
| Churchill Hospital Oxford | Oxford | Egyesült Királyság | Toboroz |
| Southampton General Hospital | Southampton | Egyesült Királyság | Toboroz |
| UK-Stoke on Trent-UHNM | Stoke-on-Trent | Egyesült Királyság | Toborzás még nem indult |
| The Royal Marsden NHSFT | Sutton | Egyesült Királyság | Toboroz |
| UK-Swindon-GWH | Swindon | Egyesült Királyság | Toborzás még nem indult |
| UK-Cornwall-RCH | Truro | Egyesült Királyság | Toboroz |
| New cross hospital wolverhampton | Wolverhampton | Egyesült Királyság | Toboroz |
| Cork University Hospital | Cork | Írország | Toboroz |
| St Vincent's University Hospital | Dublin 4 | Írország | Toboroz |
| Mater Misericordiae University Hospital | Dublin 7 | Írország | Toboroz |
| St James's Hospital | Dublin 8 | Írország | Toboroz |
| Beaumont Hospital | Dublin 9 | Írország | Toboroz |
| University Hospital Galway | Galway | Írország | Toboroz |
| University Hospital Waterford | Waterford | Írország | Toboroz |
| Azienda Ospedaliero-Universitaria delle Marche | Ancona | Olaszország | Toboroz |
| Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere Scientifico | Bologna | Olaszország | Toboroz |
| Azienda Sanitaria Territoriale Di Macerata - Ospedale Civitanova Marche | Civitanova Marche | Olaszország | Toboroz |
| ASST Grande Ospedale Metropolitano Niguarda | Milan | Olaszország | Toboroz |
| Azienda Ospedaliera Ospedali Riuniti Villa Sofia - Cervello | Palermo | Olaszország | Toboroz |
| Hospital Santa Maria Della Misericordia | Perugia | Olaszország | Toboroz |
| Azienda Sanitaria Locale di Pescara | Pescara | Olaszország | Toboroz |
| Azienda Ospedaliera Policlinico Universitario Tor Vergata | Rome | Olaszország | Toboroz |
| Azienda Ospedaliero-Universitaria Policlinico Umberto I | Rome | Olaszország | Toboroz |
| ASL Salerno-PO "Andrea Tortora" | Salerno | Olaszország | Toboroz |
| Azienda Sanitaria Universitaria Giuliano Isontina | Trieste | Olaszország | Toboroz |
| Azienda Ospedaliera Universitaria Citta Della Salute E Della Scienza Di Torino | Turin | Olaszország | Toboroz |
| Vilniaus universiteto ligonine Santaros klinikos VšĮ | Vilnius | Litvánia | Toboroz |
| Meander Medisch Centrum | Amersfoort | Hollandia | Toboroz |
| Stichting OLVG | Amsterdam | Hollandia | Toboroz |
| Amsterdam UMC Stichting | Amsterdam | Hollandia | Toboroz |
| Rijnstate Ziekenhuis Stichting | Arnhem | Hollandia | Toboroz |
| Amphia Hospital | Breda | Hollandia | Toboroz |
| Reinier de Graaf Groep | Delft | Hollandia | Toboroz |
| Albert Schweitzer Ziekenhuis | Dordrecht | Hollandia | Toboroz |
| Máxima Medisch Centrum | Eindhoven | Hollandia | Toboroz |
| Medisch Spectrum Twente | Enschede | Hollandia | Toboroz |
| Admiraal De Ruyter Ziekenhuis B.V. | Goes | Hollandia | Toboroz |
| Universitair Medisch Centrum Groningen | Groningen | Hollandia | Toboroz |
| Medisch Centrum Leeuwarden B.V. | Leeuwarden | Hollandia | Toboroz |
| Leids Universitair Medisch Centrum (LUMC) | Leiden | Hollandia | Toboroz |
| Academisch Ziekenhuis Maastricht | Maastricht | Hollandia | Toboroz |
| Sint Antonius Ziekenhuis Stichting | Nieuwegein | Hollandia | Toboroz |
| Radboud universitair medisch centrum Stichting | Nijmegen | Hollandia | Toboroz |
| Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) | Rotterdam | Hollandia | Toboroz |
| Haga Hospital | 's-Gravenhage | Hollandia | Toboroz |
| Jeroen Bosch Ziekenhuis Stichting | 'S-Hertogenbosch | Hollandia | Toboroz |
| Universitair Medisch Centrum Utrecht | Utrecht | Hollandia | Toboroz |
| Isala Klinieken Stichting | Zwolle | Hollandia | Toboroz |
| Helse Bergen HF | Bergen | Norvégia | Toboroz |
| Vestre Viken HF | Drammen | Norvégia | Toboroz |
| Akershus University Hospital | Loerenskog | Norvégia | Toboroz |
| Oslo University Hospital HF | Oslo | Norvégia | Toboroz |
| Helse Stavanger HF | Stavanger | Norvégia | Toboroz |
| Universitetssykehuset Nord-Norge HF | Tromsoe | Norvégia | Toboroz |
| St. Olavs hospital HF | Trondheim | Norvégia | Toboroz |
| Sahlgrenska University Hospital-Vaestra Goetalandsregionen | Goteborg | Svédország | Toboroz |
| Karolinska University Hospital | Huddinge | Svédország | Toboroz |
| Region Skane Skanes Universitetssjukhus | Lund | Svédország | Toboroz |
| Uppsala University Hospital | Uppsala | Svédország | Toboroz |
| US-Atlanta GA-EMORY | Atlanta | Egyesült Államok | Toboroz |
| US-Baltimore MD-UMGCCC | Baltimore | Egyesült Államok | Toboroz |
| US-Chapel Hill-UNCNORTHCAROLINA | Chapel Hill | Egyesült Államok | Toboroz |
| US-Cincinnati OH-CINCY | Cincinnati | Egyesült Államok | Toboroz |
| US-Colombus OH-OSU | Columbus | Egyesült Államok | Toboroz |
| US-Dallas TX-SOUTHWESTERN | Dallas | Egyesült Államok | Toborzás még nem indult |
| US-Kansas City KS-KUMC | Fairway | Egyesült Államok | Toborzás még nem indult |
| US-Jacksonville FL-MAYOFL | Jacksonville | Egyesült Államok | Toborzás még nem indult |
| US-Los Angeles CA-UCLA | Los Angeles | Egyesült Államok | Toborzás még nem indult |
| US-Pittsburgh PA-PITT | Pittsburgh | Egyesült Államok | Toboroz |
| US-Portland OR-OHSU | Portland | Egyesült Államok | Toborzás még nem indult |
| US-Rochester MN-MAYOMN | Rochester | Egyesült Államok | Toborzás még nem indult |
| US-San Francisco CA-UCSF | San Francisco | Egyesült Államok | Toborzás még nem indult |
| US-Wheeling WV-WVU | Wheeling | Egyesült Államok | Toboroz |
Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.